Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Update

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the recipient of a significant increase in short interest during the month of April. As of April 30th, there was short interest totaling 199,019 shares, an increase of 170.3% from the April 15th total of 73,622 shares. Based on an average daily volume of 9,855,381 shares, the days-to-cover ratio is currently 0.0 days. Approximately 2.3% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC acquired a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 2.55% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Capstone Therapeutics Price Performance

NASDAQ:CAPS opened at $0.30 on Friday. The stock has a market cap of $4.33 million, a PE ratio of -0.08 and a beta of -1.52. Capstone Therapeutics has a one year low of $0.29 and a one year high of $3.29. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.26 and a current ratio of 1.00. The stock has a 50 day moving average price of $0.54 and a 200 day moving average price of $0.69.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.